MITSUI-CHEMICALS
Mitsui Chemicals Inc. (Location: Minato-ku, Tokyo; President & CEO: Tsutomu Tannowa) announced that Mitsui Chemicals Catalysis Science Awards will begin accepting applications for the “2020 Mitsui Chemicals Catalysis Science Awards” on September 2nd via web site of the company.
In 2004, Mitsui Chemicals established the “Mitsui Chemicals Catalysis Science Awards,” which aim at contributing to the sustainable development of chemistry and the chemical industry. In particular, the awards include the “Catalysis Science Award” and “Catalysis Science Award for Creative Work,” which recognize outstanding achievements in catalysis science.
We set the subheading of the 2020 Awards as “Catalysis Science Contributing to Sustainable Society,” to highlight the social issues including plastic waste management to which the chemical industry could contribute. We welcome applications from a variety of research fields including solid catalysts, molecular catalysts, and biocatalysts, as well as green processes and rare metal utilization via catalysis, along with materials science and development through novel catalysis.
Web Entry for the Awards https://www.mitsuichem.com/en/techno/csa/index.htm
1. Awards
|
Mitsui Chemicals
|
Mitsui Chemicals
|
Eligible applicants |
- Researchers who have made extraordinary achievements in the catalysis science fields as defined in the subheading, or researchers affiliated with a public research institution - One winner (every other year) - Must be 47 years old or younger as of April 1, 2019 |
- Researchers who made original achievements in the catalysis science fields as defined in the subheading, or researchers affiliated with a public research institution - Up to two winners (every other year) - Must be 37 years old or younger as of April 1, 2019 |
Prize |
A plaque and cash prize of 5 million yen |
A plaque and cash prize of 1 million yen |
2. Selection schedule
The winners will be selected by a selection committee organized by Mitsui Chemicals, Inc., to consist of several world-class academic experts in catalysis science and a representative of Mitsui Chemicals.
Web entry start |
September 2nd , 2019 |
Deadline |
December 31st , 2019 |
Announcement of winners |
Around June 2020 on the website, specialized magazines, etc. |
Award ceremony and Commemorative lectures |
The winners will be requested to deliver commemorative lectures in Autumn 2020. The travel expenses including accommodation charges will be paid. The details will be announced later. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005450/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press release
The disruption generated by AI enables the acceleration and industrialisation of the creation of internal solutions and start-ups through centres of excellence in Chicago, Madrid and Tbilisi.This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the depl
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release
Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release
Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve
Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release
Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
